Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
TargetMol | Compound Library

Covalent Inhibitor Library

Catalog No. L9410

Covalent inhibitors are small organic molecules which interact with specific target proteins and form a covalent bond, resulting an alteration of the protein conformation and subsequently inhibit the protein activity. With some exceptions, protein modification by covalent inhibitors is usually irreversible. Covalent inhibitors possess significant advantages over non-covalent inhibitors, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. Consequently, there has been a reluctance to apply a covalent mode of action in drug discovery programs and avoided by the pharmaceutical industry. Although the majority of successful covalent drugs were discovered through serendipity in phenotypic screens, and their molecular mechanisms were elucidated afterwards, covalent drugs have made a major impact on human health and have been highly successful drugs for the pharmaceutical industry over the last 100 years, such as penicillin, omeprazole, clopidogrel, aspirin, fluorouracil, and third generation of irreversible EGFR tyrosine kinase inhibitor AZD9291/Osimertinib. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. It appears that irreversible inhibitors may maintain activity against drug-resistant mutations that are acquired after treatment with reversible inhibitors. Irreversible inhibition has important and potentially advantageous consequences for drug pharmacodynamics in which the level and frequency of dosing relates to the extent and duration of the resulting pharmacological effect. The unique pharmacodynamic feature of covalent inhibitors might bring certain practical advantages. The prolonged duration of drug action on the target effectively uncouples the pharmacodynamics of the drug from the pharmacokinetics of exposure, as target inhibition persists after the drug has been cleared. This property of covalent drugs enables less frequent dosing and the potential for lower drug doses. In addition, more and more studies have found that many major diseases, such as malignant tumors, are regulated by kinases, and these enzymes have also become the most attractive drug targets. Over the past decade, covalent kinase inhibitors (CKI) have seen a resurgence in drug discovery. Current FDA approved CKIs will bring the dawn to cancer chemotherapy. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery. The irreversible covalent inhibitor molecule is divided into two parts: a seeker and a warhead. After entering the body, the seeker and the target protein binding site first form a non-covalent interaction, and then the warhead forms an irreversible covalent bond with the nucleophilic residues of target protein. Common warheads include Michael acceptors, Sulfonyl fluoride, disulfide bond, etc. The structure and mechanism of reversible covalent inhibitors are similar to irreversible covalent inhibitors, but the difference is that the covalent binding to the target protein is reversible. The warheads for reversible covalent inhibitors are reversible nucleophilic addition reaction receptors such as cyano group and ketone carbonyl group. The reversibility of its covalent binding to the target makes its pharmacokinetics fall in between irreversible covalent inhibitors and non-covalent inhibitors. To a certain extent, reversible covalent inhibitors share the advantages of irreversible covalent inhibitors in the prolonged duration of action and the potential for lower drug doses, while reducing the risk of toxicity caused by off-target. TargetMol collects 1920 small molecules including identified covalent inhibitors and other molecules having covalent reactive groups as warheads, such as chloroacetyl,2-Chloropropionyl,Acryloyl,alkyne,sulfonyl fluoride, acrylamide, ketocarbonyl,disulfide bond, etc.

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.

Resource Download
Library compound info
Excel
PDF
Contact us for more batch information

Catalog No. L9410

Covalent Inhibitor Library
sizeIn stock
  • 1 mg
  • 30 μL x 10 mM (in DMSO)
  • 50 μL x 10 mM (in DMSO)
  • 100 μL x 10 mM (in DMSO)
  • 250 μL x 10 mM (in DMSO)
Inquiry & Custom

Top Publication Citing
Use of TargetMol Products

Cite scientific literature on TargetMol products

View More

Product Description Product Description

  • A unique collection of 1920 covalent Inhibitors and other molecules with common warheads like chloroacetyl,2-Chloropropionyl,Acryloyl,sulfonyl fluoride, alkyne,acrylamide, ketocarbonyl,disulfide bond, etc.
  • Structurally diverse with some covalent inhibitors approved by the FDA
  • Detailed compound information with structure, target, IC50, and biological activity description
  • NMR and HPLC/LCMS validated to ensure high purity

Packaging And Storage | TargetMol Packaging And Storage

  • Powder or pre-dissolved DMSO solutions in 96/384 well plate with optional 2D barcode
  • Shipped with blue ice

Library Customization | TargetMol Library Customization

Compound Library | TargetMol
Targetmol Compound Libraries
can be highly customized!
Inquiry & Custom

Library Customization | TargetMol Library Composition

Apoptosis
Antibacterial
Antibiotic
Endogenous Metabolite
Autophagy
EGFR
NF-κB
Antifungal
HIV Protease
Reactive Oxygen Species
Parasite
VEGFR
DNA/RNA Synthesis
COX
BTK
Influenza Virus
Dehydrogenase
Proteasome
PDGFR
P450
FGFR
Antioxidant
Raf
Epigenetic Reader Domain
Microtubule Associated
Estrogen/progestogen Receptor
Calcium Channel
Ferroptosis
CDK
STAT
PI3K
ERK
AChR
c-Kit
Ras
Caspase
JAK
HDAC
Anti-infection
Phosphatase
p38 MAPK
Nucleoside Antimetabolite/Analog
PKC
TRP/TRPV Channel
SARS-CoV
BCL
mTOR
ribosome
FLT
Progesterone Receptor
ATPase
Cysteine Protease
Akt
Potassium Channel
Histone Methyltransferase
Src
PDE
HSV
MAO
ROS
HSP
IκB/IKK
Phospholipase
Monoamine Oxidase
HER
HCV Protease
Adrenergic Receptor
Glucocorticoid Receptor
MMP
Androgen Receptor
Antiviral
AMPK
TNF
c-RET
Tyrosinase
HIF/HIF Prolyl-Hydroxylase
JNK
Estrogen Receptor/ERR
Wnt/beta-catenin
PPAR
Drug Metabolite
DUB
AChE
5-HT Receptor
Nrf2
GABA Receptor
NOS
Proton pump
Virus Protease
HBV
IL Receptor
TGF-beta/Smad
Mitophagy
Reverse Transcriptase
P2Y Receptor
RAAS
Transferase
PARP
Bcr-Abl
Mitochondrial Metabolism
E1/E2/E3 Enzyme
Opioid Receptor
GluR
P-gp
Prostaglandin Receptor
Trk receptor
Beta Amyloid
Chloride channel
c-Met/HGFR
Reductase
Glutathione Peroxidase
Integrin
Serine Protease
Topoisomerase
IRE1
Tyrosine Kinases
CXCR
Lipoxygenase
Interleukin
STING
CCR
MAPK
NO Synthase
HIF
DNA Methyltransferase
p53
S1P Receptor
Adenosine Receptor
PKA
Immunology/Inflammation related
Antifection
IGF-1R
Telomerase
Histone Acetyltransferase
HMG-CoA Reductase
Retinoid Receptor
Cannabinoid Receptor
NOD
Sodium Channel
NOD-like Receptor (NLR)
Carbonic Anhydrase
DNA Alkylator/Crosslinker
BACE
PERK
Pim
CSF-1R
Glucosidase
DPP-4
DNA Alkylation
Aurora Kinase
CaMK
Acyltransferase
PROTAC Linker
Hedgehog/Smoothened
FAAH
Epoxide Hydrolase
Indoleamine 2,3-Dioxygenase (IDO)
c-Fms
PDK
ALK
PLK
S6 Kinase
DNA-PK
LPL Receptor
GTPase
GSK-3
Mdm2
Dopamine Receptor
Histone Demethylase
iGluR
Aryl Hydrocarbon Receptor
Gamma-secretase
P2X Receptor
Smo
Fatty Acid Synthase
BCRP
Beta-Secretase
Isocitrate Dehydrogenase (IDH)
ATM/ATR
MEK
IRAK
Casein Kinase
Aromatase
CRISPR/Cas9
GPR
Hydroxylase
TAM Receptor
Thrombin
Adenylyl cyclase
ROR
Histamine Receptor
Tie-2
c-Myc
Thyroid hormone receptor(THR)
CAT
EBI2/GPR183
DprE1
Amino Acids and Derivatives
Ligands for Target Protein for PROTAC
Lipase
IDO
RIP kinase
UGT
NMDAR
MRP
Rho
Leukotriene Receptor
FXR
NAMPT
FLAP
Glucagon Receptor
Chk
cAMP
ATP Citrate Lyase
TLR
LRRK2
Sirtuin
transporter
Decarboxylase
PAK
OX Receptor
Lipid
Aminopeptidase
CD73
Ephrin Receptor
Pyroptosis
Acetyl-CoA Carboxylase
MLK
RSV
GPX
Adenosine deaminase
Complement System
FAK
PROTACs
Transaminase
Monocarboxylate transporter
DHFR
MALT
Dynamin
CRM1
Arginase
RAR/RXR 
Cell wall
NADPH
gp120/CD4
TOPK
ABC
NPC1L1
YAP
LTR
Necroptosis
Galectin
Antifolate
Serine/threonin kinase
Glucokinase
RANKL/RANK
ROCK
IAP
Myosin
DNA gyrase
VDAC
cell cycle arrest
Liver X Receptor
Glutaminase
SIK
PAFR
Haspin Kinase
Monoamine Transporter
Guanylate cyclase
Neuropeptide Y Receptor
Vasopressin Receptor
Somatostatin
Xanthine Oxidase
DNA
PGE Synthase
Glutathione reductase
Free radical scavengers
CPT
cGAS
MAGL
Bombesin Receptor
Thioredoxin
PTEN
PAD
ACK
Neprilysin
PI4K
KLF
SGK
cholecystokinin
AhR
CFTR
PKM
MELK
Hippo pathway
Ligand for E3 Ligase
Melanocortin Receptor
Oxytocin Receptor
Aquaporin
ROS Kinase
PD-1/PD-L1
Kinesin

Keywords